On October 5, 2023 ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, reported that management will be participating in one-on-one meetings at Bank of America’s Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023 (Press release, ProfoundBio, OCT 5, 2023, View Source [SID1234635699]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to participating in the BofA conference to speak with selected potential investors in advance of our upcoming data presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in November 2023, where we will present data on our ADC programs, including interim Phase 1 data for our lead anti-folate receptor alpha ADC program, rinatabart sesutecan." said Baiteng Zhao, PhD, CEO of ProfoundBio. "We believe our innovative ADC technology platforms have the potential to lead to highly differentiated ADC therapeutics with improved clinical outcomes, and we’re excited to share our emerging clinical data."